Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II • MC Services corporate website
4539
post-template-default,single,single-post,postid-4539,single-format-standard,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,qode-restaurant-1.0,tribe-no-js,client-news,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-13.0,qode-theme-bridge,bridge-child,wpb-js-composer js-comp-ver-5.4.4,vc_responsive

21 Mar Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II

Posted at 09:06h in Client News by